PET scan imaging in oncology

被引:73
作者
Jerusalem, G
Hustinx, R
Beguin, Y
Fillet, G
机构
[1] CHU Sart Tilman, Div Hematol & Med Oncol, Dept Med, B-4000 Liege, Belgium
[2] Univ Liege, Div Nucl Med, Dept Med, B-4000 Liege, Belgium
关键词
fluorodeoxyglucose; positron emission tomography; staging;
D O I
10.1016/S0959-8049(03)00374-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the emergence of positron emission tomography (PET) from research laboratories into routine clinical use, it is important to redefine the most appropriate use of each imaging technique. The aim of this review article is to show the potential of PET in oncology. We discuss the most promising indications and the perspectives for the future. We will also point out the shortcomings and the important questions to be answered before fully considering PET as a necessary tool in the day-to-day practice of oncology. Although many studies have documented the high accuracy of F-18-FDG PET for the detection and staging of malignant tumours and for the monitoring of therapy results in these patients, it is very important to assess the impact of the technique on patient outcome and to show cost-effectiveness from the societal viewpoint. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1525 / 1534
页数:10
相关论文
共 68 条
[1]   Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors [J].
Aassar, OS ;
Fischbein, NJ ;
Caputo, GR ;
Kaplan, MJ ;
Price, DC ;
Singer, MI ;
Dillon, WP ;
Hawkins, RA .
RADIOLOGY, 1999, 210 (01) :177-181
[2]   Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma [J].
Acland, KM ;
Healy, C ;
Calonje, E ;
O'Doherty, M ;
Nunan, T ;
Page, C ;
Higgins, E ;
Russell-Jones, R .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2674-2678
[3]  
Ahuja V, 1998, CANCER, V83, P918, DOI 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.3.CO
[4]  
2-#
[5]   Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-D-glucose [J].
Avril, N ;
Dose, J ;
Janicke, F ;
Ziegler, S ;
Romer, W ;
Weber, W ;
Herz, M ;
Nathrath, W ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1204-1209
[6]   PET imaging of gene expression [J].
Blasberg, R .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (16) :2137-2146
[7]   Functional ultrasound methods in oncological imaging [J].
Blomley, MJK ;
Eckersley, RJ .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (16) :2108-2115
[8]  
Bohuslavizki KH, 2000, J NUCL MED, V41, P816
[9]  
BOYER MJ, 2002, P AN M AM SOC CLIN, V20, pA309
[10]   Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation [J].
Cook, GJR ;
Fogelman, I ;
Maisey, MN .
SEMINARS IN NUCLEAR MEDICINE, 1996, 26 (04) :308-314